The well-known businessman and TV personality told the White House that the US needs to ‘stop doing business with the big three PBMs,’ helping to fight the drug industry’s battle against the middlemen with a friendlier face not associated directly with the brand industry.

In year two, Humira biosimilar uptake – or the lack thereof – continues to build the case for policy reform to incentivize use of cheaper biologics in the outpatient setting.

From illegal importation under FDCA to possible ERISA, HIPAA and ACA violations – a task force led by CancerCare is pushing regulatory agencies with levers to go after employer plans use of alternative funding programs for specialty drugs, which they say violate multiple federal laws. 

New coalition of smaller PBMs champions federal policies requiring ‘100% pass-through’ of rebates, with PBMs then paid by a flat, disclosed fee.